TrialClinical drug investigation2018

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.

Viktoria Moschetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.